Browse NSAIDs Content

CHPA has issued a statement in response to a recent, observational NSAID study published in the journal Science Translational Medicine.

May 17, 2022

CHPA is writing to request that FDA exercise its enforcement discretion and not take enforcement action against companies choosing to include a warning related to pregnancy on monograph product labels.

Jun 2, 2021

The results of nearly all recent observational studies of patients from around the world diagnosed with COVID-19 show no association between exposure to NSAIDs (including ibuprofen) and worsening clinical outcomes.

Jun 23, 2020

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

Jul 10, 2015

In considering the safety of NSAIDs, the use of OTC NSAIDs should be clearly distinguished from long-term prescription NSAID use. OTC medicines have a different overall benefit-to-risk equation and a wider margin of safety than prescription NSAIDs.

Feb 17, 2005

Find frequently asked questions about OTC oral pain relievers and fever reducers including acetaminophen, aspirin, ibuprofen, ketoprofen, and naproxen sodium.

FDA Announcement of a proposed safety-based Administrative Order to update the pregnancy warning labeling for NSAID-containing drug products.

FDA headquarters sign in Washington DC

The Annual Forecast for Planned Monograph Activities describes planned monograph activities that FDA intends to address over the ensuing three years.

Filter Results